MARKET

ONCR

ONCR

Oncorus, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.87
-0.57
-3.47%
Opening 13:19 02/26 EST
OPEN
16.65
PREV CLOSE
16.44
HIGH
16.98
LOW
15.21
VOLUME
139.91K
TURNOVER
--
52 WEEK HIGH
37.86
52 WEEK LOW
14.60
MARKET CAP
346.69M
P/E (TTM)
-7.9753
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 19)
Benzinga · 02/19 12:25
DJ Oncorus Shares Drop 15% After Public Offering Prices
Dow Jones · 02/12 18:17
Oncorus Secures $57M Via Equity At 9% Discount
Benzinga · 02/12 14:31
Oncorus raises $57M through equity offering
Oncorus (ONCR) has priced 3M common shares offering at $19/share, for expected gross proceeds of $57M.Underwriters' over-allotment is an additional 450K shares.Offering is expected to close on February 17.Previously: Oncorus
Seekingalpha · 02/12 10:27
BRIEF-Oncorus Announces Pricing Of Public Offering Of Common Stock
reuters.com · 02/12 03:24
Oncorus Is a Biopharma Company Focused on Cancer Immunotherapies
Oncorus Is a Biopharma Company Focused on Cancer Immunotherapies
Dow Jones · 02/12 03:22
Jefferies, Evercore ISI, Piper Sandler Are Joint Bookrunners Managers for Oncorus Offering
Jefferies, Evercore ISI, Piper Sandler Are Joint Bookrunners Managers for Oncorus Offering
Dow Jones · 02/12 03:22
Oncorus Has Granted Underwriters Option to Buy Up to 450,000 More Shares
Oncorus Has Granted Underwriters Option to Buy Up to 450,000 More Shares
Dow Jones · 02/12 03:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCR. Analyze the recent business situations of Oncorus, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCR stock price target is 38.67 with a high estimate of 45.00 and a low estimate of 31.00.
EPS
Institutional Holdings
Institutions: 47
Institutional Holdings: 19.47M
% Owned: 89.12%
Shares Outstanding: 21.85M
TypeInstitutionsShares
Increased
0
0
New
47
19.47M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.11%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
Chairman/Founder/Executive Director
Mitchell Finer
President/Chief Executive Officer
Theodore Ashburn
Chief Financial Officer/Primary Contact
John McCabe
Chief Operating Officer
Steve Harbin
Chief Scientific Officer
Christophe Queva
Vice President
Lorena Lerner
Director
Scott Canute
  • Dividends
  • Splits
  • Insider Activity
No Data
About ONCR
Oncorus, Inc. is a clinical stage biopharmaceutical company focused on developing viral immunotherapies for cancer patients. The Company is leveraging its platforms to develop a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. The Company is developing a differentiated portfolio of locally and systemically administered oncolytic virus therapies across its oncolytic Herpes Simplex Virus (oHSV) and Synthetic Virus Platform. Its lead product candidates are ONCR-177, ONCR-GBM, Synthetic Coxsackievirus (CV)A21 and Synthetic Seneca Valley Virus (SVV).

Webull offers kinds of Oncorus Inc stock information, including NASDAQ:ONCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCR stock methods without spending real money on the virtual paper trading platform.